• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Tasked with steadying BIO, Rachel King faces biotech’s many challenges

cafead

Administrator
Staff member
  • cafead   Jun 07, 2023 at 10:22: AM
via As the lobbying group holds its annual meeting in Boston, BIO’s interim leader is trying to focus attention back on the industry’s most pressing priorities.

article source